Get the Stockscreener App
26.52
18.55%
3.9833
Centessa Pharmaceuticals Plc Adr stock is traded at $26.52, with a volume of 6.41M.
It is up +18.55% in the last 24 hours and up +19.77% over the past month.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
See More
Previous Close:
$22.54
Open:
$22.34
24h Volume:
6.41M
Relative Volume:
4.79
Market Cap:
$3.55B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-17.00
EPS:
-1.56
Net Cash Flow:
$-160.51M
1W Performance:
+18.65%
1M Performance:
+19.77%
6M Performance:
+103.20%
1Y Performance:
+57.18%
1-Day Range:
$21.97
$27.18
1-Week Range:
$21.59
$27.18
52-Week Range:
$9.60
$27.18
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals Plc Adr
Sector
Industry
Phone
44 7391 789784
Address
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
26.49 | 3.00B | 0 | -151.09M | -160.51M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.03 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.76 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
897.82 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
374.54 | 36.43B | 4.56B | -176.77M | 225.30M | -1.7177 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Aug-29-25 | Resumed | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| May-28-25 | Initiated | Needham | Buy |
| May-08-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-31-25 | Initiated | Piper Sandler | Overweight |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Sep-20-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Jul-18-24 | Initiated | Oppenheimer | Outperform |
| Nov-15-23 | Upgrade | Jefferies | Hold → Buy |
| Oct-26-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jun-21-23 | Initiated | Evercore ISI | Outperform |
| Jun-12-23 | Initiated | Guggenheim | Buy |
| Mar-17-23 | Initiated | SVB Securities | Outperform |
| Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
| Feb-11-22 | Initiated | Goldman | Neutral |
View All
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Latest News
Centessa Pharmaceuticals stock hits 52-week high at $25.44 By Investing.com - Investing.com South Africa
Centessa prices public offering of 11.6 million ADSs at $21.50 each - Investing.com India
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares - GlobeNewswire Inc.
Centessa Pharmaceuticals stock falls after announcing public offering By Investing.com - Investing.com South Africa
Centessa Pharmaceuticals stock falls after announcing public offering - Investing.com
Centessa Pharmaceuticals launches public offering of ADSs - Investing.com India
What is Leerink Partnrs’ Estimate for CNTA FY2025 Earnings? - Defense World
Centessa Pharmaceuticals plc ADR (CNTA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - setenews.com
Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Gap Down Following Weak Earnings - Defense World
Centessa Pharmaceuticals Down Over 16%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk - 富途牛牛
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 52-Week HighTime to Buy? - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 25.35 USD By Investing.com - Investing.com Australia
Centessa Pharmaceuticals stock hits 52-week high at 25.35 USD - Investing.com
Centessa Pharmaceuticals (CNTA) – Research Analysts’ Weekly Ratings Changes - Defense World
Mario Alberto Accardi Sells 8,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock - MarketBeat
Centessa Pharma (CNTA) president sells $200k in shares - Investing.com India
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at $24.65 - Investing.com India
Centessa Pharmaceuticals stock hits 52-week high at $24.65 By Investing.com - Investing.com Philippines
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by TD Asset Management Inc - MarketBeat
There is no doubt that Centessa Pharmaceuticals plc ADR (CNTA) ticks all the boxes. - setenews.com
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Bought by Windmill Hill Asset Management Ltd - MarketBeat
Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Stake Reduced by GAMMA Investing LLC - Defense World
Centessa Pharmaceuticals (CNTA) Receives a Buy from Piper Sandler - The Globe and Mail
Tanager Wealth Management LLP Decreases Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Platinum Investment Management Ltd. Has $3.82 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Wells Fargo Sticks to Its Buy Rating for Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 12-Month HighWhat's Next? - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 24.17 USD By Investing.com - Investing.com Nigeria
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of “Buy” by Brokerages - Defense World
Centessa Pharmaceuticals stock hits 52-week high at 24.17 USD - Investing.com India
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 1-Year HighTime to Buy? - MarketBeat
Centessa Pharmaceuticals’ Bush sells $840,000 in shares - Investing.com India
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) CTO Sells $840,000.00 in Stock - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month HighHere's What Happened - MarketBeat
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 1-Year High – Should You Buy? - Defense World
Insider Selling: Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells 8,172 Shares of Stock - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 23.51 USD By Investing.com - Investing.com Australia
Centessa Pharmaceuticals (NASDAQ:CNTA) General Counsel Iqbal J. Hussain Sells 6,000 Shares - MarketBeat
Centessa Pharmaceuticals stock hits 52-week high at 23.51 USD - Investing.com
Woodline Partners LP Lowers Stock Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Accardi Mario Alberto | President, Orexin Program |
Oct 27 '25 |
Sale |
25.00 |
8,000 |
200,000 |
194,394 |
2.48%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):